RxDoctor Payments Data

Sally Knooihuizen, MD

Gastroenterology · Lincoln, NENPI 1164943171

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Aimmune Therapeutics, Inc. at 27.2% of the total. That places this record below the midpoint for gastroenterology clinicians in NE, where the typical reported total is $2,374.

$1,966in general payments, 2019–2025

Across 79 payments — averaging $24.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aimmune Therapeutics, Inc.$535
  • Johnson & Johnson$323
  • AbbVie$182
  • Takeda Pharmaceuticals U.S.A., Inc.$158
  • Nestle Healthcare Nutrition Inc.$130
  • Sanofi$121
  • plus $518 from 15 others

What the payments were for

  • Food & beverage$1,966100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,966 in reported general payments places this provider in the 45th percentile of 89 gastroenterology providers in Nebraska.

See all gastroenterology providers in Nebraska

Medicare billing

Part B allowed, 2024
$397,064
Medicare patients
344
Services billed
14,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase12$16,003
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates146$9,210
Omeprazole81$1,207
Pantoprazole Sodium38$468
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl15$325
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl18$324
Famotidine17$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$182$16,00312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 89 gastroenterology providers in Nebraska.

Other gastroenterology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →